膜杰作
Star Staining
分子别名（Synonym）
C-C motif chemokine 3,MIP1-(a),AI323804,CCL3,chemokine (C-C motif) ligand 3,G0S19-1,LD78a,LD78alpha,MIP1 alpha,MIP-1 alpha,MIP1A,MIP-1alpha,MIP1-alpha
表达区间及表达系统（Source）
Human CCL3, His Tag (CC3-H5249) is expressed from E. coli cells. It contains AA Ser 24 - Ala 92 (Accession # P10147-1).
Predicted N-terminus: Met
Request for sequence
蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the N-terminus
The protein has a calculated MW of 9.7 kDa. The protein migrates as 12-13 kDa under reducing (R) condition (SDS-PAGE).
内毒素（Endotoxin）
Less than 0.1 EU per μg by the LAL method.
纯度（Purity）
>95% as determined by SDS-PAGE.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in 20 mM Tris,150 mM NaCl,0.2 M Arginine,1 mM EDTA,pH8.0 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
电泳（SDS-PAGE）
Human CCL3, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
背景（Background）
CCL3, also know as MIP-1-alpha, is monokine with inflammatory and chemokinetic properties. CCL3 is an important chemokine implicated in both immune surveillance and tolerance, has emerged as a prognostic biomarker in both solid and hematological malignancies. Binds to CCR1, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant MIP-1-alpha induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV).
